Buonora Sibelle, Nogueira Susie, Pone Marcus Vinicius, Aloé Marisa, Oliveira Ricardo Hugo, Hofer Cristina
Department of Pediatrics, Federal University of Rio de Janeiro, Brazil.
Ann Trop Paediatr. 2008 Mar;28(1):59-64. doi: 10.1179/146532808X270699.
Growth failure in HIV-infected children is an important factor in either initiating or changing antiretroviral therapy (ART). This study assesses the impact of HIV infection on growth parameters of adolescents who acquired HIV vertically.
This retrospective, longitudinal study involved adolescents aged 10-20 years with vertically-acquired HIV infection who were followed up in one of the three main referral centres for paediatric HIV/AIDS in Rio de Janeiro, Brazil. Length, weight and variables related to demographic, clinical and laboratory issues were analysed.
108 subjects were enrolled. Median age was 12.7 years, median duration of follow-up was 97.2 months and 61 (56.5%) were female. The difference between the baseline and final weight Z-scores was -0.31 (p=0.02). Patients with final weight Z-scores < or = -2 used more ART regimens (average 4.13) than those with Z-scores > -2 (average 2.90, p<0.01) and also had a lower final CD4+ cell percentage--average 19% vs 24% (p<0.01), respectively. The difference between baseline and final-height Z-scores was -0.27 (p<0.01). Several factors were associated with a final-height Z-score < or = -2: clinical stage C during follow-up (RR 1.60, 95% CI 1.11-2.31), chronic diarrhoea during follow-up (RR 2.02, 95% CI 1.04-3.90), HAART use (RR 1.41, 95% CI 1.16-1.71), number of ART regimens (p<0.01) and final CD4+ cell percentage (p<0.01). In multivariate analysis, presentation in clinical stage C during follow-up was the only significant variable (OR 4.04, 95% CI 1.23-13.28).
Even on HAART, HIV-infected adolescents have lower growth parameters than the normal population and this is associated with a worse prognosis.
感染艾滋病毒儿童的生长发育迟缓是启动或改变抗逆转录病毒疗法(ART)的一个重要因素。本研究评估了垂直感染艾滋病毒对青少年生长参数的影响。
这项回顾性纵向研究纳入了年龄在10至20岁之间、垂直感染艾滋病毒的青少年,他们在巴西里约热内卢的三个主要儿科艾滋病毒/艾滋病转诊中心之一接受随访。分析了身高、体重以及与人口统计学、临床和实验室问题相关的变量。
共纳入108名受试者。中位年龄为12.7岁,中位随访时间为97.2个月,61名(56.5%)为女性。基线体重Z评分与最终体重Z评分之间的差异为-0.31(p=0.02)。最终体重Z评分≤-2的患者使用的抗逆转录病毒治疗方案更多(平均4.13种),高于Z评分>-2的患者(平均2.90种,p<0.01),且其最终CD4+细胞百分比也更低,分别为平均19%和24%(p<0.01)。基线身高Z评分与最终身高Z评分之间的差异为-0.27(p<0.01)。有几个因素与最终身高Z评分≤-2相关:随访期间临床分期为C期(RR 1.60,95%CI 1.11-2.31)、随访期间慢性腹泻(RR 2.02,95%CI 1.04-3.90)、使用高效抗逆转录病毒治疗(HAART)(RR 1.41,95%CI 1.16-1.71)、抗逆转录病毒治疗方案的数量(p<0.01)以及最终CD4+细胞百分比(p<0.01)。在多变量分析中,随访期间临床分期为C期是唯一的显著变量(OR 4.04,95%CI 1.23-13.28)。
即使接受了HAART治疗,感染艾滋病毒的青少年的生长参数仍低于正常人群,且这与更差的预后相关。